Five Prime Therapeutics, Inc. logo
Five Prime Therapeutics, Inc. FPRX

Five Prime Therapeutics, Inc. Financial Statements 2011-2026 | FPRX

Annual Financial Statements Five Prime Therapeutics, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

616 M 169 M 384 M 584 M 1.19 B 923 M 549 M 82.5 M - -

Shares

36.8 M 35 M 34 M 27.9 M 27 M 25.7 M 20.9 M 5.52 M - -

Net Income

-84.3 M -137 M -140 M -150 M -65.7 M 250 M -37.4 M -28.9 M -27.6 M 19.7 M

Revenue

13.2 M 14.9 M 49.9 M 39.5 M 30.7 M 380 M 19.2 M 13.8 M 9.98 M 64.9 M

EBITDA

-87 M -137 M -141 M -149 M -97.5 M 289 M -36 M -27.7 M -26.2 M 21.3 M

Operating Expenses

106 M 157 M 196 M 191 M 130 M 92.8 M 56.8 M 43.2 M 37.8 M 45.3 M

General and Administrative Expenses

40.6 M 42.7 M 39.7 M 40 M 35.8 M 22.6 M 13.6 M 10.4 M 9.01 M 11.2 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Five Prime Therapeutics, Inc. FPRX
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Five Prime Therapeutics, Inc. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.5 0.45 % $ 862 M canadaCanada
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 3.83 1.32 % $ 105 M schweizSchweiz
Agenus Agenus
AGEN
$ 3.64 9.31 % $ 108 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 35.08 -0.36 % $ 2.03 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.39 0.36 % $ 357 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.95 -11.63 % $ 266 B britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 1.57 -5.42 % $ 94.3 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.08 1.38 % $ 79.9 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 331.14 3.85 % $ 43.4 B usaUSA
Altimmune Altimmune
ALT
$ 3.4 1.8 % $ 300 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.99 0.81 % $ 107 M usaUSA
Amgen Amgen
AMGN
$ 344.03 -1.12 % $ 185 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.27 -1.68 % $ 3.85 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.99 1.28 % $ 220 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 73.8 -0.55 % $ 1.43 B usaUSA
Annexon Annexon
ANNX
$ 5.56 1.0 % $ 862 M usaUSA
Annovis Bio Annovis Bio
ANVS
$ 2.56 12.28 % $ 52.6 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.88 -5.16 % $ 4.8 M chinaChina
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.7 -1.87 % $ 4.58 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.12 -0.24 % $ 441 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.14 1.31 % $ 223 M israelIsrael
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ardelyx Ardelyx
ARDX
$ 5.99 0.84 % $ 1.44 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
argenx SE argenx SE
ARGX
$ 749.99 0.48 % $ 25 B niderlandNiderland
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.06 1.82 % $ 3.06 B usaUSA
Arvinas Arvinas
ARVN
$ 10.87 0.14 % $ 771 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 60.28 -1.23 % $ 8.06 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 29.51 1.72 % $ 331 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.62 1.82 % $ 8.71 B australiaAustralia